

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	24	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:07:17 ON 11 OCT 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:07:37 ON 11 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s phenylephrine

L1 44 PHENYLEPHRINE

=> s phenylephrine/cn

L2 1 PHENYLEPHRINE/CN

=> s phenylephrine hcl/cn

L3 0 PHENYLEPHRINE HCL/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 59-42-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzenemethanol, 3-hydroxy- $\alpha$ -[(methylamino)methyl]-, ( $\alpha$ R)-  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenemethanol, 3-hydroxy- $\alpha$ -[(methylamino)methyl]-, (R)-

CN Benzyl alcohol, m-hydroxy- $\alpha$ -[(methylamino)methyl]-, (-)- (7CI, 8CI)

OTHER NAMES:

CN (-)-m-Hydroxy- $\alpha$ -(methylaminomethyl)benzyl alcohol

CN (-)-m-Oxedrine

CN (-)-m-Synephrine

CN (-)-Phenylephrine

CN (R)-(-)-Phenylephrine

CN (R)-Phenylephrine

CN 1-m-Hydroxy- $\alpha$ -[(methylamino)methyl]benzyl alcohol

CN L-Phenylephedrine


CN 1-Phenylephrine

CN m-Methylaminoethanolphenol

\* \* \* \* \* STN Columbus \* \* \* \* \*

CN m-Oxedrine  
 CN m-Sympathol  
 CN m-Sympatol  
 CN m-Synephrine  
 CN Mesaton  
 CN Mesatone  
 CN Metaoxedrin  
 CN Metaoxedrine  
 CN Metasympatol  
 CN Metasynephrine  
 CN Mezaton  
 CN Neo-Synephrine  
 CN Phenylephrine  
 CN R(-)-Mezaton  
 CN Visadron  
 FS STEREOSEARCH  
 MF C9 H13 N O2  
 CI COM  
 SR CAS EARLY REGISTRATIONS  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO,  
 CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
 DDFU, DRUGU, EMBASE, GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB,  
 IMSCOSEARCH, IPA, MEDLINE, MRCK\*, NAPRALERT, PHAR, PROMT, RTECS\*,  
 SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL,  
 USPATOLD, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7056 REFERENCES IN FILE CA (1907 TO DATE)  
 61 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 7066 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s hydrocortisone/cn  
 L4 1 HYDROCORTISONE/CN

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 50-23-7 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11 $\beta$ )- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Cortisol (8CI)  
 OTHER NAMES:  
 CN 11 $\beta$ ,17,21-Trihydroxypregn-4-ene-3,20-dione  
 CN 11 $\beta$ ,17,21-Trihydroxyprogesterone

CN 11 $\beta$ ,17 $\alpha$ ,21-Trihydroxypregn-4-ene-3,20-dione  
 CN 11 $\beta$ -Hydroxycortisone  
 CN 17-Hydroxycorticosterone  
 CN 17 $\alpha$ -Hydroxycorticosterone  
 CN 4-Pregnene-11 $\beta$ ,17 $\alpha$ ,21-triol-3,20-dione  
 CN Acticort  
 CN Aeroseb HC  
 CN Ala-Cort  
 CN Anflam  
 CN Anti-inflammatory hormone  
 CN CaldeCort Spray  
 CN CCN 90306A  
 CN Cetacort  
 CN Cobadex  
 CN Cort-Dome  
 CN Cortanal  
 CN Cortef  
 CN Cortenema  
 CN Corticreme  
 CN Cortifan  
 CN Cortiment  
 CN Cortispray  
 CN Cortonema  
 CN Cortril  
 CN Dermacort  
 CN Dermocortal  
 CN Dermolate  
 CN Dihydrocostisone  
 CN Dioderm  
 CN Domolene-HC  
 CN Efcorbin  
 CN Efcortelan  
 CN Eldecort  
 CN Epiderm H  
 CN Esiderm H  
 CN Evacort  
 CN Ficortril  
 CN Genacort  
 CN HC  
 CN Heb-Cort  
 CN Hidro-Colisona  
 CN Hycort  
 CN Hycortol  
 CN Hycortole  
 CN Hydracort  
 CN Hydrasson  
 CN Hydro-Adreson  
 CN Hydrocortisone

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
 DISPLAY

FS STEREOSEARCH

DR 8056-08-4, 8063-42-1, 80562-38-5

MF C21 H30 O5

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS,  
 BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*, DRUGU,  
 EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,  
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, PHAR,  
 PIRA, PROMT, PS, RTECS\*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER,  
 USAN, USPAT2, USPATFULL, USPATOLD, VETU

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

39613 REFERENCES IN FILE CA (1907 TO DATE)  
372 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
39687 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
20 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s ichthammol/cn

L5 1 ICHTHAMMOL/CN

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 8029-68-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN Ichthammol (CA INDEX NAME)

OTHER NAMES:

CN Albichthol

CN Albichtol

CN Albikhtol

CN Ammonium bithiolcium

CN Ammonium bithiolicum

CN Ammonium ichthosulfonate

CN Ammonium ichthyolate

CN Ammonium sulfobituminate

CN Ammonium sulfoichthyolate

CN Amsubit

CN Bitulan

CN Bituminol

CN Bitumol

CN Hirathiol

CN Ichden

CN Ichtammon

CN Ichthadone

CN Ichthalum

CN Ichthammonium

CN Ichthium

CN Ichthosan

CN Ichthosauran

CN Ichthosulfol

CN Ichthymall

CN Ichthyn

CN Ichthynat

CN Ichthyol

CN Ichthyolsulfonic acid, ammonium salt

CN Ichthyopon

CN Ichthysalle

CN Ichtipur

CN Leukochthol  
 CN Lithol  
 CN Perichthol  
 CN Petrosulpho  
 CN Piscarol  
 CN Pisciol  
 CN Saurol  
 CN Subitol  
 CN Sulfofenol  
 CN Sulfoichthyolic acid, ammonium salt  
 CN Thilaven  
 CN Thiolin  
 CN Thiosept  
 CN Thiozin  
 CN Trasulphane  
 CN Tumenol  
 DEF A complex product obtained by the sulfonation and ammoniation of the distillation product from bituminous schists. It may contain saturated and unsaturated hydrocarbons, nitrogen bases and thiophene derivatives.  
 DR 1394-96-3  
 MF Unspecified  
 CI COM, MAN  
 LC STN Files: AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK\*, PIRA, PROMT, RTECS\*, SCISEARCH, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 302 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 302 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 17:07:17 ON 11 OCT 2007)

FILE 'REGISTRY' ENTERED AT 17:07:37 ON 11 OCT 2007

L1 44 S PHENYLEPHRINE  
 L2 1 S PHENYLEPHRINE/CN  
 L3 0 S PHENYLEPHRINE HCL/CN  
 L4 1 S HYDROCORTISONE/CN  
 L5 1 S ICHTHAMMOL/CN

=> fil medl capl

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	31.50	31.71

FILE 'MEDLINE' ENTERED AT 17:08:57 ON 11 OCT 2007

FILE 'CAPLUS' ENTERED AT 17:08:57 ON 11 OCT 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> fil medl capl uspatful wpid

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.86	32.57

FILE 'MEDLINE' ENTERED AT 17:09:05 ON 11 OCT 2007

FILE 'CAPLUS' ENTERED AT 17:09:05 ON 11 OCT 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:09:05 ON 11 OCT 2007  
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 17:09:05 ON 11 OCT 2007  
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=> s 12  
L6 18129 L2

=> s 14; s 15  
L7 93719 L4

L8 382 L5

=> s 16 and 17 and 18  
L9 22 L6 AND L7 AND L8

=> dup rem 19  
PROCESSING COMPLETED FOR L9  
L10 18 DUP REM L9 (4 DUPLICATES REMOVED)

=> d ti tot

L10 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1  
TI Composition and method for topical treatment of tar-responsive dermatological disorders

L10 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2  
TI Pharmaceutical compositions containing N-(phosphonoalkyl)-amino acids

L10 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Pharmaceutical compositions comprising o-acetylsalicyl derivatives of amino saccharides and amino acids

L10 ANSWER 4 OF 18 USPATFULL on STN  
TI Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids

L10 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions containing N-acyl-alldosamine or N-acylamino acid compounds

L10 ANSWER 6 OF 18 USPATFULL on STN  
TI Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions

L10 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3  
TI Topical treatment of dermatological disorders associated with reactive or dilated blood vessels

L10 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Acidic drug complexes for improved bioavailability and delivery

L10 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Non-amphoteric glutathione derivative compositions for topical application

L10 ANSWER 10 OF 18 USPATFULL on STN  
TI Bioavailability and improved delivery of acidic pharmaceutical drugs



L10 ANSWER 11 OF 18 USPATFULL on STN  
 TI Oligosaccharide aldonic acids and their topical use

L10 ANSWER 12 OF 18 USPATFULL on STN  
 TI Non-amphoteric glutathione derivative compositions for tropical application

L10 ANSWER 13 OF 18 USPATFULL on STN  
 TI Urea composition

L10 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4  
 TI N-Acetyl cysteine and its topical use

L10 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Urea compositions for the treatment of skin disorders

L10 ANSWER 16 OF 18 USPATFULL on STN  
 TI Oligosaccharide aldonic acids and their topical use

L10 ANSWER 17 OF 18 USPATFULL on STN  
 TI Oligosaccharide aldonic acids and their topical use

L10 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use

=> d ibib abs 7

L10 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3  
 ACCESSION NUMBER: 2004:934335 CAPLUS  
 DOCUMENT NUMBER: 141:388761  
 TITLE: Topical treatment of dermatological disorders associated with reactive or dilated blood vessels  
 INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004220259	A1	20041104	US 2004-817479	20040402
WO 2004093722	A2	20041104	WO 2004-US10454	20040405
WO 2004093722	A3	20050331		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-460322P P 20030404  
 US 2004-817479 A 20040402

OTHER SOURCE(S): MARPAT 141:388761

AB The invention provides a method of topically treating a dermatol.

disorder. The method includes topically applying a therapeutically effective amount of a cosmetic or dermatol. composition to an affected area of the skin. The composition includes at least one compound that is (i) a polyhydroxy-alldonic acid, (ii) a polyhydroxy-alldonic lactone, (iii) a polyhydroxy-allduronic acid, (iv) a polyhydroxy-allduronic lactone, (v) a polyhydroxy-alldaric acid; (vi) a polyhydroxy-alldaric lactone, and (vii) an organic acid lactone having two or more hydroxyl or ketohydroxyl groups. The dermatol. disorder treated is one associated with reactive or dilated blood vessels. Also included in the invention are methods of treating dermatol. disorders associated with reactive blood vessels that include topical application of a therapeutically effective amount of a composition

=> d ti tol5

'TO15' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d ibib abs 15

L10 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:836770 CAPLUS

DOCUMENT NUMBER: 139:341739

TITLE: Urea compositions for the treatment of skin disorders

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086291	A2	20031023	WO 2003-US10823	20030409
WO 2003086291	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2481702	A1	20031023	CA 2003-2481702	20030409
AU 2003220691	A1	20031027	AU 2003-220691	20030409
US 2004033963	A1	20040219	US 2003-409684	20030409
EP 1492486	A2	20050105	EP 2003-717012	20030409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-371157P	P 20020410
			WO 2003-US10823	W 20030409

AB The invention is directed to compns., methods of making the compns., and methods of treating cosmetic and dermatol. disorders with a composition that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are stable when compared to conventional urea-containing compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and

galacturonic acid 8 g was slowly added to form a mol. complex until the solution changed pH from 7.4 to 1.9. A clear solution containing the mol. complex was mixed with a hydrophilic ointment.

=> d ibib abs 18

L10 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:31287 CAPLUS

DOCUMENT NUMBER: 134:105670

TITLE: Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001932	A2	20010111	WO 2000-US16301	20000628
WO 2001001932	A3	20010517		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6335023	B1	20020101	US 2000-487228	20000119
CA 2373852	A1	20010111	CA 2000-2373852	20000628
BR 2000011640	A	20020514	BR 2000-11640	20000628
EP 1227820	A2	20020807	EP 2000-950220	20000628
EP 1227820	B1	20060419		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503436	T	20030128	JP 2001-507430	20000628
AU 775620	B2	20040805	AU 2000-63353	20000628
CN 1635864	A	20050706	CN 2000-809776	20000628
AT 323498	T	20060515	AT 2000-950220	20000628
EP 1685843	A1	20060802	EP 2006-6895	20000628
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1227820	T	20060831	PT 2000-950220	20000628
ES 2262529	T3	20061201	ES 2000-950220	20000628
US 2002028227	A1	20020307	US 2001-987023	20011113
US 6740327	B2	20040525		
MX 2001PA13042	A	20030820	MX 2001-PA13042	20011217
HK 1048764	A1	20060915	HK 2003-100874	20030206
US 2004180854	A1	20040916	US 2004-811998	20040330
AU 2004212601	A1	20041014	AU 2004-212601	20040920
AU 2004212601	B2	20070614		
JP 2005232180	A	20050902	JP 2005-74658	20050316
PRIORITY APPLN. INFO.:			US 1999-141264P	P 19990630
			US 2000-487228	A 20000119
			AU 2000-63353	A 20000628
			EP 2000-950220	A3 20000628
			JP 2001-507430	A3 20000628
			WO 2000-US16301	W 20000628

OTHER SOURCE(S): MARPAT 134:105670

AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

=&gt; s wound

L11 747005 WOUND

=&gt; d his

(FILE 'HOME' ENTERED AT 17:07:17 ON 11 OCT 2007)

FILE 'REGISTRY' ENTERED AT 17:07:37 ON 11 OCT 2007

L1 44 S PHENYLEPHRINE  
L2 1 S PHENYLEPHRINE/CN  
L3 0 S PHENYLEPHRINE HCL/CN  
L4 1 S HYDROCORTISONE/CN  
L5 1 S ICHTHAMMOL/CN

FILE 'MEDLINE, CAPLUS' ENTERED AT 17:08:57 ON 11 OCT 2007

FILE 'MEDLINE, CAPLUS, USPATFULL, WPIDS' ENTERED AT 17:09:05 ON 11 OCT 2007

L6 18129 S L2  
L7 93719 S L4  
L8 382 S L5  
L9 22 S L6 AND L7 AND L8  
L10 18 DUP REM L9 (4 DUPLICATES REMOVED)  
L11 747005 S WOUND

=&gt; s l11 and l6 and l7

L12 19 L11 AND L6 AND L7

=&gt; s l11 and l8

L13 40 L11 AND L8

=&gt; s l11 (S) l8

L14 10 L11 (S) L8

=&gt; dup rem l14

PROCESSING COMPLETED FOR L14

L15 10 DUP REM L14 (0 DUPLICATES REMOVED)

=&gt; d ibib abs 9-10

L15 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1928:25631 CAPLUS

DOCUMENT NUMBER: 22:25631

ORIGINAL REFERENCE NO.: 22:2987g-h

TITLE: Effect of certain drugs on the healing of wounds

AUTHOR(S): Kobayashi, Ekizo

SOURCE: Ber. ges. Physiol. exptl. Pharmakol. (1927), 44, 149

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB Drugs were applied in salve form to an aseptic wound produced on the rabbit's ear by complete removal of the skin. Healing was promoted by HgCl<sub>2</sub>, AgNO<sub>3</sub>, thymol, resorcinol, protargol, KMnO<sub>4</sub>, CHI<sub>3</sub>, PhOH, lysol, cresol, naphthol, salicylic acid, balsam of Peru, orthoform and cocaine in small, and B<sub>2</sub>O<sub>3</sub> and ichthyol in moderate, doses and inhibited by large doses. Tissue was frequently destroyed by large doses. Chloral hydrate inhibits healing even in 0.1% solution

L15 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1917:1894 CAPLUS

DOCUMENT NUMBER: 11:1894

ORIGINAL REFERENCE NO.: 11:367h

TITLE: Use of glycerol and ichthyol in the treatment of septic wounds

AUTHOR(S): Daman, Thomas W. A.

SOURCE: British Medical Journal (1916), II, 646-7

CODEN: BMJOAE; ISSN: 0007-1447

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB A discussion of the osmosis-inducing properties of glycerol mixts.

=> d ibib ab5-8

'AB5-8' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

CLASS ----- IPC, NCL, ECLA, FTERM

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

IND ----- Indexing data

IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE

PATS ----- PI, SO

SAM ----- CC, SX, TI, ST, IT

SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels

IMAX ----- MAX, indented with text labels

ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and

its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field  
codes. For a list of the display field codes, enter HELP DFIELDS at  
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;  
TI,IND; TI,SO. You may specify the format fields in any order and the  
information will be displayed in the same order as the format  
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,  
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC  
to view a specified Accession Number.  
ENTER DISPLAY FORMAT (BIB):abs

L15 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
AB A wound treatment composition contains one or more antimicrobial agents that  
alone or in combination have antibacterial and antifungal properties, a  
vasoconstriction agent, a steroidal anti-inflammatory, a stimulant, and a  
carrier. The wound treatment composition may optionally include a demulcent  
agent and a skin disinfectant agent. A process of manufacturing a wound  
treatment composition is also disclosed. A wound treatment composition  
contained  
base ointment 42.70, polymyxin B sulfate and bacitracin zinc in a ratio of  
20 parts polymyxin B sulfate to 1 part bacitracin zinc 25.00, 0.3%  
8-hydroxyquinoline sulfate solution 0.30, benzoin tincture 11.70, ichthammol  
6.25, hydrocortisone (micronized) 1.00, 0.25% phenylephrine HCl 0.25, and  
10% povidone-iodine solution 12.80%.

=> d ibib abs 5-8

L15 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1996:724210 CAPLUS  
DOCUMENT NUMBER: 125:339089  
TITLE: Oily base-containing compositions for protection of  
excreta- or tissue exudate-induced mucosa inflammation  
or wound worsening in the rectum or vagina  
INVENTOR(S): Samejima, Teruyuki; Anase, Kazumasa; Oomachi, Kengo;  
Kase, Naotake; Noda, Etsunosuke  
PATENT ASSIGNEE(S): Tendo Seiyaku Kk, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08245369	A	19960924	JP 1995-78095	19950308
PRIORITY APPLN. INFO.:			JP 1995-78095	19950308

AB Oily base-containing compns. for protection of excreta- or tissue  
exudate-induced mucosa inflammation or wound worsening in the rectum or  
vagina comprise oily bases, gelling agents, and active ingredients. A  
suppository contained hydrocortisone acetate 5, lidocaine 30,  
dibucaine-HCl 5, tocopherol acetate 60, light anhydrous silica 52.5 and hard  
fats 1597.5 mg.

L15 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:503414 CAPLUS  
DOCUMENT NUMBER: 113:103414  
TITLE: Film-forming composition containing iodine for wound healing  
INVENTOR(S): Ilizarov, G. A.; Kusturov, V. I.; Uvarova, E. S.  
PATENT ASSIGNEE(S): Kurgan Scientific-Research Institute of Experimental and Clinical Orthopedics and Traumatology, USSR  
SOURCE: U.S.S.R. From: Otkrytiya, Izobret. 1990, (5), 36-7.  
CODEN: URXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1540830	A1	19900207	SU 1985-3893293	19850306
PRIORITY APPLN. INFO.:			SU 1985-3893293	19850306
AB	A film-forming composition containing pure iodine and collodion for treating postoperative wounds is improved. The healing time is shortened by adding ichthyol, sea buckthorn oil, and gramicidin C to the composition. Thus, the composition contains pure iodine 0.3, ichthyol 1.4, sea buckthorn oil 2.4-20.0, gramicidin C 1.0-2.0 weight%, and the balance collodion.			

L15 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:600530 CAPLUS  
DOCUMENT NUMBER: 99:200530  
TITLE: Wound-healing compositions containing povidone-iodine  
INVENTOR(S): Knutson, Richard A.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 31,162, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4401651	A	19830830	US 1980-171261	19800722
AU 8057398	A	19801023	AU 1980-57398	19800411
AU 536885	B2	19840531		
SE 8002847	A	19801019	SE 1980-2847	19800416
SE 451178	B	19870914		
SE 451178	C	19880107		
JP 55141409	A	19801105	JP 1980-51086	19800416
JP 06017299	B	19940309		
BE 882829	A1	19800818	BE 1980-200262	19800417
NO 8001112	A	19801020	NO 1980-1112	19800417
FR 2454303	A1	19801114	FR 1980-8657	19800417
FR 2454303	B1	19841228		
GB 2048070	A	19801210	GB 1980-12755	19800417
GB 2048070	B	19830901		
CH 653892	A5	19860131	CH 1980-2978	19800417
SU 1709895	A3	19920130	SU 1980-2909300	19800417
CA 1125650	A1	19820615	CA 1980-350131	19800418
IL 59881	A	19831230	IL 1980-59881	19800418
IN 152625	A1	19840225	IN 1980-CA449	19800418
AT 8002106	A	19880315	AT 1980-2106	19800418
AT 386744	B	19881010		
PRIORITY APPLN. INFO.:			US 1979-31162	A2 19790418

AB An ointment that promotes wound healing contains sucrose [57-50-1] and an

antimicrobial such as povidone-iodine [25655-41-8]. Clin. experiences are detailed for an ointment prepared by mixing 2 lb 10% providone-iodine solution and 5 lb 10% providone-iodine ointment with 20 lb sugar.

L15 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1928:25630 CAPLUS  
DOCUMENT NUMBER: 22:25630  
ORIGINAL REFERENCE NO.: 22:2987g-h  
TITLE: Effect of certain drugs on the healing of wounds  
AUTHOR(S): Kobayashi, Ekizo  
SOURCE: Folia pharmacol. japon. (1927), 6, 183-92  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

AB Drugs were applied in salve form to an aseptic wound produced on the rabbit's ear by complete removal of the skin. Healing was promoted by HgCl<sub>2</sub>, AgNO<sub>3</sub>, thymol, resorcinol, protargol, KMnO<sub>4</sub>, CHI<sub>3</sub>, PhOH, lysol, cresol, naphthol, salicylic acid, balsam of Peru, orthoform and cocaine in small, and B2O<sub>3</sub> and ichthyol in moderate, doses and inhibited by large doses. Tissue was frequently destroyed by large doses. Chloral hydrate inhibits healing even in 0.1% solution

=> s l11 and l6 (s) l7

L16 0 L11 AND L6 (S) L7

=> dup rem l12

PROCESSING COMPLETED FOR L12

L17 17 DUP REM L12 (2 DUPLICATES REMOVED)

=> d ibib abs 10-17

L17 ANSWER 10 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:239054 USPATFULL  
TITLE: Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum  
INVENTOR(S): Soloviev, Evgeny Vladimirovich, 2, rue des Capucins, F-92190, Meudon, FRANCE  
Shcherbinin, Vladimir Viktorovich, Leninsky prosp., 83, art. 46, Moscow, 117261, RUSSIAN FEDERATION  
Chernyshev, Evgeny Andreevich, Leninsky prosp., 61/1, art. 54, Moscow, 117333, RUSSIAN FEDERATION  
Kotrelev, Mikhail Vladimirovich, ul. B. Bronnaya, 5, art. 12, Moscow, 103104, RUSSIAN FEDERATION  
Pavlov, Konstantin Vitalevich, Moscow, RUSSIAN FEDERATION  
Khromova, Nataliya Yurievna, Moscow, RUSSIAN FEDERATION  
Komalenkova, Nina Georgievna, Moscow, RUSSIAN FEDERATION  
PATENT ASSIGNEE(S): Soloviev, Evgeny Vladimirovich, Meudon, FRANCE (non-U.S. individual)  
Shcherbinin, Vladimir Viktorovich, Moscou, RUSSIAN FEDERATION (non-U.S. individual)  
Chernyshev, Evgeny Andreevich, Moscou, RUSSIAN FEDERATION (non-U.S. individual)  
Kotrelev, Mikhail Vladimirovich, Moscou, RUSSIAN FEDERATION (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451850	B1	20020917
	WO 2000010561		20000302
APPLICATION INFO.:	US 2001-763222		20010514 (9)
	WO 1998-EP5214		19980817
			20010514 PCT 371 date
DOCUMENT TYPE:	Utility		



FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Reamer, James H.  
LEGAL REPRESENTATIVE: Greer, Burns & Crain, Ltd.  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1,19  
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 1334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention applies to medicine, more specifically, to pharmacology and it can be applied for the expansion of therapeutic effects spectrum, strengthening of therapeutic effect and a decrease of medicaments' toxicity. For realization of the method, a patient is treated with a medicament complex with derivatives of 1-germa-2,8,9-trioxa-5-azatricyclo[3.3.3.0.sup.1.5]undecane or with derivatives of 1-germa-2,8 dioxo-5 azabicyclo[3.3.0.sup.1.5]octane in doses of 0.001÷0.1 g per day. In doing so, biologically active compounds which are contained in food products, in hygienic and cosmetic remedies, in medicinal herbs and plants can be used as a medicament component. The method allows a considerable increase of complex pharmacological activity of medicaments for a wide diversity of diseases and decrease of the medicaments' toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:115775 USPATFULL  
TITLE: In situ formation of polymeric material  
INVENTOR(S): Dettmar, Peter William, Hull, UNITED KINGDOM  
Jolliffe, Ian Gordon, Hull, UNITED KINGDOM  
Skaugrud, Oyvind, Mjoendalen, NORWAY  
PATENT ASSIGNEE(S): Reckitt Benckiser Healthcare (UK) Limited, Slough,  
UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391294	B1	20020521
	WO 9909962		19990304
APPLICATION INFO.:	US 2000-485771		20000412 (9)
	WO 1998-GB2410		19980810
			20000412 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-17626	19970821
	GB 1997-17627	19970821
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Di Nola Baron, Liliana	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	865	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutically acceptable bio-adhesive coating, film or gel is formed in situ at a body surface by the reaction of (i) an anionic polymer or tripolyphosphate and (ii) a cationic polymer in the presence of water. The two components are supplied either as separate aqueous solutions or in a single non-aqueous formulation, which can be a liquid suspension tablet, capsule or powder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:936 USPATFULL  
TITLE: Oligosaccharide aldonic acids and their topical use  
INVENTOR(S): Yu, Ruey J., 4 Lindenwold Ave., Ambler, PA, United States 19002  
Van Scott, Eugene J., 3 Hidden La., Abington, PA, United States 19001

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335023	B1	20020101
APPLICATION INFO.:	US 2000-487228		20000119 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141264P	19990630 (60)
	US 1999-141264P	19990630 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Qazi, Sabiha	
LEGAL REPRESENTATIVE:	Hunton & Williams	
NUMBER OF CLAIMS:	123	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2835	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compositions comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:31287 CAPLUS  
DOCUMENT NUMBER: 134:105670  
TITLE: Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use  
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001932	A2	20010111	WO 2000-US16301	20000628
WO 2001001932	A3	20010517		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,			

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6335023	B1	20020101	US 2000-487228	20000119
CA 2373852	A1	20010111	CA 2000-2373852	20000628
BR 2000011640	A	20020514	BR 2000-11640	20000628
EP 1227820	A2	20020807	EP 2000-950220	20000628
EP 1227820	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503436	T	20030128	JP 2001-507430	20000628
AU 775620	B2	20040805	AU 2000-63353	20000628
CN 1635864	A	20050706	CN 2000-809776	20000628
AT 323498	T	20060515	AT 2000-950220	20000628
EP 1685843	A1	20060802	EP 2006-6895	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1227820	T	20060831	PT 2000-950220	20000628
ES 2262529	T3	20061201	ES 2000-950220	20000628
US 2002028227	A1	20020307	US 2001-987023	20011113
US 6740327	B2	20040525		
MX 2001PA13042	A	20030820	MX 2001-PA13042	20011217
HK 1048764	A1	20060915	HK 2003-100874	20030206
US 2004180854	A1	20040916	US 2004-811998	20040330
AU 2004212601	A1	20041014	AU 2004-212601	20040920
AU 2004212601	B2	20070614		
JP 2005232180	A	20050902	JP 2005-74658	20050316
PRIORITY APPLN. INFO.:			US 1999-141264P	P 19990630
			US 2000-487228	A 20000119
			AU 2000-63353	A 20000628
			EP 2000-950220	A3 20000628
			JP 2001-507430	A3 20000628
			WO 2000-US16301	W 20000628
			US 2001-987023	A1 20011113

OTHER SOURCE(S): MARPAT 134:105670

AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

L17 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2001:220710 USPATFULL

TITLE: Local anesthetic formulations

INVENTOR(S): Kohane, Daniel S., Newton, MA, United States  
Berde, Charles B., Brookline, MA, United States  
Strichartz, Gary, Sherborn, MA, United States  
Langer, Robert S., Newton, MA, United States

PATENT ASSIGNEE(S): Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)  
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326020	B1	20011204
APPLICATION INFO.:	US 1998-79622		19980515 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-46761P 19970516 (60)  
US 1997-46163P 19970516 (60)  
US 1997-46683P 19970516 (60)  
US 1997-53462P 19970723 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Joynes, R.  
LEGAL REPRESENTATIVE: Holland & Knight LLP  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 1381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Combinations of naturally occurring site 1 sodium channel blockers, such as tetrodotoxin (TTX), saxitoxin (STX), decarbamoyl saxitoxin, and neosaxitoxin (referred to jointly herein as "toxins"), with other agents, have been developed to give long duration block with improved features, including safety and specificity. In one embodiment, duration of block is greatly prolonged by combining a toxin with a local anesthetic, vasoconstrictor, glucocorticoid, and/or adrenergic drugs, both alpha agonists (epinephrine, phenylephrine), beta-blockers (propranolol), and mixed central-peripheral alpha-2 agonists (clonidine), or other agents. In another embodiment, the duration of nerve block from toxin can be greatly enhanced by the inclusion of amphiphilic or lipophilic solvents. In still another embodiment, the effectiveness of these compositions is enhanced by microencapsulation within polymeric carriers, preferably biodegradable synthetic polymeric carriers. Modality specific nerve block can be obtained using combinations of toxin with vanilloids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:144730 CAPLUS  
DOCUMENT NUMBER: 132:189687  
TITLE: Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum  
INVENTOR(S): Soloviev, Evgeny Vladimirovich; Shcherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich; Kotrelev, Mikhail Vladimirovich; Pavlov, Konstantin Vitalevich; Khromova, Nataliya Yurievna; Komalenkova, Nina Georgievna  
PATENT ASSIGNEE(S): Fr.  
SOURCE: PCT Int. Appl., 52 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010561	A1	20000302	WO 1998-EP5214	19980817
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9893432	A1	20000314	AU 1998-93432	19980817
EP 1105117	A1	20010613	EP 1998-946360	19980817

R: CH, DE, FR, GB, LI  
RU 2233286 C2 20040727 RU 2001-107254 19980817  
US 6451850 B1 20020917 US 2001-763222 20010514  
PRIORITY APPLN. INFO.: WO 1998-EP5214 A 19980817  
OTHER SOURCE(S): MARPAT 132:189687

AB A substance for therapeutic, prophylactic, alimentary and cosmetic uses comprises a complex of a medicament or biol. active compound with an organogermanium compound (OGC), with the general formula of  $Lk(OGC)_m(solv)_n$  (L = medicament, solv = water or organic solvent, k, m =  $\geq 1$ , n  $\geq 0$ ). The complex can be applied for expansion of therapeutic effects spectrum, strengthening of therapeutic effect and decrease of medicament toxicity. An organogermanium compound corresponds to, e.g., 1-germa-2,8,9-trioxa-5-azatricyclo[3.3.3.0<sup>1,5</sup>]undecane or 1-germa-2,8-dioxa-5-azabicyclo[3.3.0<sup>1,5</sup>]octane in the doses of 0.001-0.1 g per day. The method allows considerable increase of complex pharmacol. activity of medicaments for a wide diversity of diseases and decrease of the medicaments toxicity. For example, complexes of OGC with tranquilizers (diazepam, mezepam, phenazepam, etc.) were more efficient compared to initial tranquilizers concerning decrease of insomnia, suppression of phobia, anxiety, agitation and tensivity, and also showed anti-inflammatory, antihypoxic, immunostimulating, repairing, and nootropic effects.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 1998:115761 USPATFULL

TITLE: Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor

INVENTOR(S): Thomas, Peter G., Charlottesville, VA, United States

PATENT ASSIGNEE(S): Cytos Pharmaceuticals LLC, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5811446		19980922
APPLICATION INFO.:	US 1997-839805		19970418 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Covington, Raymond		
LEGAL REPRESENTATIVE:	Angres, Isaac A., Petraglia, Susan P.		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1037		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for protecting the eye from degenerative eye conditions by administering prophylactic histidine compositions. The invention also relates to methods for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compositions. The invention relates further still to novel histidine compositions for carrying out the present methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:618371 CAPLUS

DOCUMENT NUMBER: 129:255004

TITLE: Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor

INVENTOR(S): Thomas, Peter G.

PATENT ASSIGNEE(S): Cytos Pharmaceuticals LLC, USA

SOURCE: U.S., 10 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

CODEN: USXXAM

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811446	A	19980922	US 1997-839805	19970418
WO 9847366	A1	19981029	WO 1998-US7319	19980417
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9873583	A	19981113	AU 1998-73583	19980417
PRIORITY APPLN. INFO.:			US 1997-839805	A 19970418
			WO 1998-US7319	W 19980417

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 111 (S) 16  
 L18 1 L11 (S) L6

=> d

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:302852 CAPLUS  
 DN 126:282803  
 TI Topical phenylephrine preparations for stopping local bleeding from a skin wound  
 IN Armstrong, Kenneth T.; Schoenhals, Jennifer M.  
 PA Armstrong, Kenneth T., Can.; Schoenhals, Jennifer M.  
 SO Can. Pat. Appl., 18 pp.  
 CODEN: CPXXEB  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CA 2154979	A1	19970129	CA 1995-2154979	19950728
WO 9704764	A1	19970213	WO 1996-CA505	19960726
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
AU 9664109	A	19970226	AU 1996-64109	19960726
PRAI CA 1995-2154979	A	19950728		
WO 1996-CA505	W	19960726		

=> s 111 (S) 17  
 L19 95 L11 (S) L7

=> s bacitracin and l19  
L20 7 BACITRACIN AND L19

=> d ibib abs 5-7

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1997:574520 CAPLUS  
DOCUMENT NUMBER: 127:225309  
TITLE: Bioadhesive-wound healing compositions and methods for  
preparing and using same  
INVENTOR(S): Martin, Alain; Leung, Sau-hung S.  
PATENT ASSIGNEE(S): Warner-Lambert Co., USA  
SOURCE: U.S., 131 pp., Cont.-in-part of U.S. Ser. No. 298,521,  
abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 28  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5658956	A	19970819	US 1995-445824	19950522
JP 2002356421	A	20021213	JP 2002-82387	19920115
JP 2003231632	A	20030819	JP 2002-362245	19920115
CA 2194876	A1	19960307	CA 1995-2194876	19950707
WO 9606640	A1	19960307	WO 1995-US8568	19950707
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9530045	A	19960322	AU 1995-30045	19950707
AU 707353	B2	19990708		
EP 779820	A1	19970625	EP 1995-926209	19950707
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
JP 10505057	T	19980519	JP 1996-508729	19950707
NZ 290031	A	20010223	NZ 1995-290031	19950707
ZA 9507245	A	19970630	ZA 1995-7245	19950829
US 5981606	A	19991109	US 1998-19316	19980205
PRIORITY APPLN. INFO.:			US 1991-663500	B1 19910301
			US 1993-53922	B2 19930426
			US 1994-298521	B2 19940830
			JP 1992-505329	A3 19920115
			US 1994-224936	B1 19940408
			US 1995-445824	A 19950522
			WO 1995-US8568	W 19950707
			US 1997-37730P	P 19970202

AB The present invention pertains to therapeutic bioadhesive-wound healing compns. useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsatd. fatty acids. The therapeutic bioadhesive-wound healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compns. and the pharmaceutical products in which the compns. may be used.

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1996:367739 CAPLUS  
DOCUMENT NUMBER: 125:19043  
TITLE: Bioadhesive-wound healing composition  
INVENTOR(S): Leung, Sau-Hung S.; Martin, Alain

PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
 SOURCE: PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 28  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606640	A1	19960307	WO 1995-US8568	19950707
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5658956	A	19970819	US 1995-445824	19950522
AU 9530045	A	19960322	AU 1995-30045	19950707
AU 707353	B2	19990708		
EP 779820	A1	19970625	EP 1995-926209	19950707
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
JP 10505057	T	19980519	JP 1996-508729	19950707
ZA 9507245	A	19970630	ZA 1995-7245	19950829
PRIORITY APPLN. INFO.:			US 1994-298521	A 19940830
			US 1995-445824	A 19950522
			US 1991-663500	B1 19910301
			US 1993-53922	B2 19930426
			WO 1995-US8568	W 19950707

AB The present invention pertains to therapeutic bioadhesive-wound healing compns. useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsatd. fatty acids. The therapeutic bioadhesive-wound healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compns. and the pharmaceutical products in which the compns. may be used.

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:520670 CAPLUS  
 DOCUMENT NUMBER: 105:120670  
 TITLE: Omiderm, a new synthetic wound covering: physical properties and drug permeability studies  
 AUTHOR(S): Behar, D.; Juszynski, M.; Hur, N. Ben; Golan, J.; Eldad, A.; Tuchman, Y.; Sterenberg, N.; Rudensky, B.  
 CORPORATE SOURCE: Dep. Radiat. Chem., Soreq Nucl. Res. Cent., Yavne, 70600, Israel  
 SOURCE: Journal of Biomedical Materials Research (1986), 20(6), 731-8  
 CODEN: JBMRBG; ISSN: 0021-9304  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Omiderm [104220-30-6], a new synthetic wound covering based on hydrophilized polyurethane, was highly permeable to water. Values in the region of 5000 g/m<sup>2</sup> 24 h were found for the water permeability of Omiderm in comparison to 1400 and 500 g/m<sup>2</sup> 24 h for Biobrane and Op site, resp. Permeabilities of antibacterial agents through Omiderm were 2-3 orders of magnitude greater than those through Biobrane. The in vitro effectiveness of various antibacterial agents in lowering bacterial growth of different bacterial strains when applied to seeded agar plates through Omiderm membrane was investigated. NBH ointment (1% Neomycin [1404-04-2], 1% bacitracin [1405-87-4], and 0.5% hydrocortisone [50-23-7]) was the most effective material in inhibiting bacterial growth, except for



Pseudomonas aeruginosa where Ag sulfadiazine [22199-08-2] was superior.  
In in vivo expts. bacterial counts of infected wounds covered with Omiderm  
and topically treated with NBH were lowered to <103 organism/g tissue  
after 1 day of treatment.

=> s l11 and benzoin  
L21 1935 L11 AND BENZOIN

=> s l11 (S) benzoin  
L22 96 L11 (S) BENZOIN

=> dup rem l22  
PROCESSING COMPLETED FOR L22  
L23 91 DUP REM L22 (5 DUPLICATES REMOVED)

=> s l23 not py>2002  
L24 49 L23 NOT PY>2002

=> dfocus  
DFOCUS IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> focus  
PROCESSING COMPLETED FOR L24  
L25 49 FOCUS L24 1-

=> d ibib abs 1-5

L25 ANSWER 1 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN  
ACCESSION NUMBER: 1996-078393 [09] WPIDS  
DOC. NO. CPI: C1996-025977 [09]  
DOC. NO. NON-CPI: N1996-065241 [09]  
TITLE: Use of oxidised crosslinked polysaccharide - for mfr. of  
biodegradable sterile wound treatment compsn.  
DERWENT CLASS: A96; B07; D22; P34  
INVENTOR: GRUSKIN E A; JIANG Y  
PATENT ASSIGNEE: (USSU-C) US SURGICAL CORP  
COUNTRY COUNT: 5

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
EP 693291	A2	19960124	(199609)*	EN	7[0]	
US 5502042	A	19960326	(199618)	EN	5[0]	
CA 2154124	A	19960123	(199621)	EN		
EP 693291	B1	20011219	(200206)	EN		
DE 69524682	E	20020131	(200216)	DE		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 693291	A2	EP 1995-111523	19950721
US 5502042	A	US 1994-278778	19940722
CA 2154124	A	CA 1995-2154124	19950718
DE 69524682	E	DE 1995-69524682	19950721
DE 69524682	E	EP 1995-111523	19950721

FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----------	------	-----------

-----  
DE 69524682 E

Based on

EP 693291 A

PRIORITY APPLN. INFO: US 1994-278778 19940722

AN 1996-078393 [09] WPIDS

AB EP 693291 A2 UPAB: 20060111

Use of an oxidised, cross-linked polysaccharide (I) having an induced chemical charge for mfr. of a sterile wound treatment compsn. is new.

USE - The compsn. may contain one or more medico-surgically useful substances or therapeutic agents (TA) and can be used e.g. for promoting repair or reconstruction and/or new tissue growth. The TA can be e.g. an antimicrobial agent, one which enhances blood coagulation, kidney plasminogen activator, tumour necrosis factor for cancer therapy, colony stimulating factor and interferon, interleukin-2 or lymphokine to enhance the immune system or growth factor (partic. for inclusion in sutures).

ADVANTAGE - The compsn. is biodegradable.

L25 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:756482 CAPLUS

DOCUMENT NUMBER: 128:26954

TITLE: Method and composition for coating wound or protecting animal skin

INVENTOR(S): Huprich, Carl A.; Timms, Leo L.

PATENT ASSIGNEE(S): Iowa State University Research Foundation, Inc., USA

SOURCE: U.S., 2 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5688498	A	19971118	US 1996-644009	19960509
US 5942239	A	19990824	US 1997-799869	19970214

PRIORITY APPLN. INFO.: US 1996-644009 A2 19960509

AB Solns. of polyether polyurethane with benzoin gum in THF applied to animal skin provide dry films that are elastic, vapor permeable, water proof, dirt proof, insect proof, aerobic bacteriostatic and adhere well under environmental conditions. Apparent application viscosity can be adjusted as required for specific needs. The solution contains THF 100, polyether polyurethane 10, and benzoin gum 5 parts (no data).

L25 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1944:33497 CAPLUS

DOCUMENT NUMBER: 38:33497

ORIGINAL REFERENCE NO.: 38:4983c-d

TITLE: Preliminary observations on the healing properties of vitamin F [linoleic and linolenic acids] in cutaneous lesions

AUTHOR(S): Ribeiro, Fonseca; Guimaraes, Laerte M.

SOURCE: Rev. faculdade med. vet., Univ. Sao Paulo (Brazil) (1942), 2(No. 2), 41-3

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The ethyl esters of linoleic and linolenic acids mixed either with ZnO and talcum, or in equal proportions with a tincture of benzoin, stimulate wound healing and scar-tissue formation in cutaneous lesions.

L25 ANSWER 4 OF 49 USPATFULL on STN

ACCESSION NUMBER: 79:47569 USPATFULL

TITLE: Radiation and moisture curable compositions and method of use

INVENTOR(S): Brack, Karl, Holliston, MA, United States

PATENT ASSIGNEE(S): Design Cote Corporation, Natick, MA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4176212		19791127
APPLICATION INFO.:	US 1978-872197		19780125 (5)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Newsome, John H.		
LEGAL REPRESENTATIVE:	Kersey, George E.		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1,10		
LINE COUNT:	1479		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Coating compositions which are curable by simultaneous or sequential exposure to radiation and moisture. In the case of pigmented compositions, rapid curing is initiated by exposure to moderate radiation and the cure completed by exposure to moisture. The various compositions include radiation reactive groups and moisture reactive oxazolidine and isocyanate groups. The moisture reactive and radiation curable groups preferably are interpolymerized during the curing process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 5 OF 49 MEDLINE on STN  
ACCESSION NUMBER: 90254361 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2187555  
TITLE: Circumcision--which dressing?.  
AUTHOR: Gough D C; Lawton N  
CORPORATE SOURCE: Department of Paediatric Urology, Royal Manchester Children's Hospital.  
SOURCE: British journal of urology, (1990 Apr) Vol. 65, No. 4, pp. 418-9.  
Journal code: 15740090R. ISSN: 0007-1331.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: (CLINICAL TRIAL)  
(COMPARATIVE STUDY)  
(CONTROLLED CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199006  
ENTRY DATE: Entered STN: 20 Jul 1990  
Last Updated on STN: 18 Dec 2002  
Entered Medline: 28 Jun 1990

AB Three methods of circumcision dressing were compared in a prospective trial. The results showed that dressings containing tincture of benzoin adversely affected wound healing in children. Dressing the wound with greasy tulle gave better results; the addition of soframycin did not produce better results than those achieved with ordinary paraffin tulle.

=> d ibib abs 6-10

L25 ANSWER 6 OF 49 MEDLINE on STN  
ACCESSION NUMBER: 93055854 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 1430556  
TITLE: The postoperative use of wound adhesives. Gum mastic versus benzoin, USP.  
AUTHOR: Lesesne C B  
SOURCE: The Journal of dermatologic surgery and oncology, (1992 Nov) Vol. 18, No. 11, pp. 990.

Journal code: 7707501. ISSN: 0148-0812.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: (COMPARATIVE STUDY)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199212  
 ENTRY DATE: Entered STN: 22 Jan 1993  
 Last Updated on STN: 3 Jul 2002  
 Entered Medline: 9 Dec 1992

AB Our results, combined with the work of previous authors, show that gum mastic not only offers superior adhesive qualities compared with benzoin, USP but also has a lower incidence of postoperative contact dermatitis and subsequent skin discoloration. In light of the widespread use of surgical adhesives, this study is important in documenting the low incidence of complications and the advantages of gum mastic compared with benzoin, USP.

L25 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:7947 CAPLUS  
 DOCUMENT NUMBER: 102:7947  
 TITLE: Electric implement coated with electrically insulating material  
 INVENTOR(S): Sato, Kenichi; Okunoyama, Hikaru  
 PATENT ASSIGNEE(S): Toshiba Corp., Japan; Toshiba Chemical Products Co., Ltd.  
 SOURCE: U.S., 7 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4472482	A	19840918	US 1982-405083	19820804
CH 658336	A5	19861031	CH 1982-4878	19820813
PRIORITY APPLN. INFO.:			JP 1981-147006	A 19810919

AB The scattering of hardener, catalysts, monomer, etc., during the hardening of previously reported thermosetting resin-impregnated elec. insulators surrounding elec. devices causing safety problems and voids in the elec. insulators was prevented by coating the impregnated insulator with a photohardener resin, such as polyol (meth)acrylate or hydroxy-terminated polyester (meth)acrylates and hardening the photohardenable resin first. Thus, a transformer coil wound with 4 layers of 0.25-mm-thick glass tape was heated 12 h at 100°, impregnated with a thermosetting composition containing Epikote 828 [25068-38-6] (epoxy equivalent .apprx.190) 100, phthalic anhydride hardening agent 75, and Zn octylate 2 parts in a vacuum tank, dipped in a photohardening composition containing Repoxy E-1000 (a polyhydric  $\beta$ -hydroxy acrylate) 100, ethylene glycol acrylate 20, and benzoin Me ether sensitizer 3 parts, cured under an 80 W/cm high-pressure Hg lamp to give a copolymer (I) [93610-97-0] coating, and dried 5 h at 110° and 10 and 150° to give a coil with an insulating layer that showed better insulating properties during immersion in water and heating cycles from room temperature to 200° than a coil with a similar insulating layer not coated with I.

L25 ANSWER 8 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2001:32823 USPATFULL  
 TITLE: Supplemented and unsupplemented tissue sealants, methods of their production and use  
 INVENTOR(S): MacPhee, Martin James, Gaithersburg, MD, United States  
 Drohan, William Nash, Springfield, VA, United States

## PATENT ASSIGNEE(S):

Lasa, Jr., Carlos I., Quezon, Philippines  
Liau, Gene, Darnestown, MD, United States  
Haudenschild, Christian, Rockville, MD, United States  
The American National Red Cross, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197325	B1	20010306
APPLICATION INFO.:	US 1995-474084		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned Continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned Continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned Continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
ASSISTANT EXAMINER:	Zeman, Mary K		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1,2,3		
NUMBER OF DRAWINGS:	50 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	4805		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 9 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2000:121069 USPATFULL  
TITLE: Supplemented and unsupplemented tissue sealants, method of their production and use  
INVENTOR(S): MacPhee, Martin James, Gaithersburg, MD, United States  
Drohan, William Nash, Springfield, VA, United States  
Liau, Gene, Darnestown, MD, United States  
Haudenschild, Christian, Rockville, MD, United States  
PATENT ASSIGNEE(S): The American National Red Cross, Falls Church, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117425		20000912
APPLICATION INFO.:	US 1995-474086		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned		

DOCUMENT TYPE: which is a continuation-in-part of Ser. No. US  
FILE SEGMENT: 1991-798919, filed on 27 Nov 1991, now abandoned  
UTILITY  
PRIMARY EXAMINER: Woodward, M Patrick  
ASSISTANT EXAMINER: Zeman, Mary K  
LEGAL REPRESENTATIVE: Sterne, Kessler Goldstein & Fox P.L.L.C.  
NUMBER OF CLAIMS: 57  
EXEMPLARY CLAIM: 1,2,3  
NUMBER OF DRAWINGS: 53 Drawing Figure(s); 36 Drawing Page(s)  
LINE COUNT: 4910

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 10 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2000:50372 USPATFULL  
TITLE: Supplemented and unsupplemented tissue sealants, methods of their production and use  
INVENTOR(S): MacPhee, Martin James, Gaithersburg, MD, United States  
Drohan, William Nash, Springfield, VA, United States  
Woolverton, Christopher J., Kent, OH, United States  
PATENT ASSIGNEE(S): The American National Red Cross, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054122		20000425
APPLICATION INFO.:	US 1995-479034		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned And a continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Smith, Lynette F.  
ASSISTANT EXAMINER: Zeman, Mary K  
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
NUMBER OF CLAIMS: 43  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 50 Drawing Figure(s); 36 Drawing Page(s)  
LINE COUNT: 4855

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone